How does the regulatory state of PRAS40 (Thr246) affect the progression and prognosis of clear cell renal cell carcinoma?

1. What role does PRAS40 play in the mTOR signaling pathway?

PRAS40 (Proline-rich Akt substrate of 40 kDa) is a key regulatory factor in the mammalian target of rapamycin (mTOR) signaling pathway. This pathway serves as a central network within cells that integrates nutrient, energy, and growth factor signals to regulate cell growth, proliferation, and metabolism. Initially identified as a direct phosphorylation substrate of Akt kinase, PRAS40 also functions as an endogenous inhibitory protein of mTOR complex 1 (mTORC1). Its functional state is precisely regulated by phosphorylation at multiple sites, with phosphorylation at Thr246 being particularly crucial for its binding to 14-3-3 proteins and dissociation from mTORC1, thereby relieving its inhibition of mTORC1 activity and promoting downstream protein synthesis and cell growth. Given the abnormal activation of the mTOR pathway in various cancers, including renal cell carcinoma, in-depth investigation of PRAS40, especially its key phosphorylation modifications (such as Thr246), holds significant value in understanding tumorigenesis and progression. Specific recognition tools, such as the PRAS40 (T246) Recombinant Rabbit Monoclonal Antibody, provide essential means for analyzing the relationship between its active state and tumor biological behavior.

2. What are the expression characteristics and clinical relevance of PRAS40 in clear cell renal cell carcinoma?

Clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney cancer, with its development closely linked to abnormalities in the VHL/HIF pathway. Additionally, excessive activation of the mTOR signaling pathway plays a significant role. Recent bioinformatics analyses based on public databases such as The Cancer Genome Atlas (TCGA) have revealed the expression patterns of PRAS40 in ccRCC and its clinical significance.

Studies have shown that compared to normal kidney tissues, PRAS40 mRNA expression levels are significantly upregulated in ccRCC tumor tissues. This high expression state is not unrelated to patients' clinicopathological features but rather exhibits clear correlations: PRAS40 expression levels increase significantly with higher tumor T stages (e.g., T3/T4 stages compared to T1/T2 stages), advanced clinical stages, the occurrence of distant metastasis, and higher histological grades. This series of positive correlations strongly suggests that high PRAS40 expression may actively participate in the malignant progression of ccRCC, including local invasion, distant dissemination, and cellular dedifferentiation. Further receiver operating characteristic (ROC) curve analysis indicates that PRAS40 expression levels have a certain diagnostic discriminative ability for ccRCC, suggesting its potential as a diagnostic biomarker.

3. Is high PRAS40 expression independently associated with poor prognosis in clear cell renal cell carcinoma patients?

Survival analysis provides more compelling evidence for the clinical significance of PRAS40. Research demonstrates that ccRCC patients with high PRAS40 expression have significantly shorter overall survival than those with low PRAS40 expression. This implies that PRAS40 expression levels can effectively predict long-term patient outcomes.

To determine whether PRAS40 is an independent prognostic factor, researchers conducted univariate and multivariate Cox proportional hazards regression analyses. In univariate analysis, high PRAS40 expression was significantly associated with poorer overall survival. When incorporating other classic clinicopathological prognostic variables (such as TNM stage, grade, etc.) into multivariate analysis, high PRAS40 expression remained an independent, statistically significant predictor of poor prognosis. This finding is crucial, as it indicates that PRAS40 expression levels can provide prognostic information beyond traditional clinical staging. This may help identify patient subgroups with worse prognosis within high-stage groups or those with occult high risk within low-stage groups, enabling more refined risk stratification.

4. Why is the specific study of PRAS40 (Thr246) phosphorylation critically important?

The aforementioned studies based on mRNA levels reveal the association between total PRAS40 and ccRCC prognosis. However, PRAS40's function is primarily regulated by post-translational modifications, particularly phosphorylation. Therefore, investigating its key active form—phosphorylated PRAS40 (especially p-Thr246)—in tumors is more valuable for understanding its role in driving tumor mechanisms.

1. Linking upstream signals to downstream functions: Phosphorylation at Thr246 is primarily mediated by Akt and represents a critical step in the activation of mTORC1 by growth factor signals through the PI3K/Akt pathway. Detecting p-PRAS40 (Thr246) levels can more directly reflect the activation state of the PI3K/Akt/mTOR signaling pathway in tumor cells.

2. Assessing functional activity rather than mere expression levels: Highly expressed PRAS40, if mostly in an unphosphorylated inhibitory state, may have limited pro-cancer effects. Conversely, even moderate total PRAS40 expression with extremely high Thr246 phosphorylation levels could lead to strong mTORC1 signal output and pro-growth effects. Thus, using the PRAS40 (T246) Recombinant Rabbit Monoclonal Antibody to detect phosphorylation levels can more accurately assess its functional activity.

3. Revealing potential therapeutic targets and resistance mechanisms: Many drugs targeting the mTOR pathway (e.g., everolimus) or upstream pathways (e.g., VEGF/VEGFR inhibitors) are used in advanced kidney cancer treatment. The phosphorylation state of PRAS40 (Thr246) may serve as a predictive marker for these drugs' efficacy or as one of the mechanisms of acquired resistance. For example, tumor cells resistant to mTOR inhibitors may exhibit mTORC1 activation independent of PRAS40 inhibition or compensatory phosphorylation at other PRAS40 sites.

5. What are the future research directions and clinical translation prospects?

Based on current findings, future research on PRAS40 in ccRCC can focus on the following aspects:

1. In-depth mechanistic exploration: Using tools such as the PRAS40 (T246) Recombinant Rabbit Monoclonal Antibody, validate p-PRAS40 (Thr246) protein levels in ccRCC cell lines and tissue microarrays to determine whether they align with mRNA expression trends and correlate with clinicopathological features and prognosis. Functional experiments (e.g., overexpression, knockdown, phosphorylation site mutations) can clarify the direct effects of PRAS40 and its Thr246 phosphorylation on ccRCC cell proliferation, invasion, migration, and sensitivity to targeted drugs.

2. Exploring its potential as a therapeutic target: Given its natural role as an mTORC1 inhibitor, developing small molecules that stabilize PRAS40 binding to mTORC1 or mimic its inhibitory conformation may represent a novel treatment strategy. Simultaneously, investigate how to modulate PRAS40 phosphorylation by targeting its upstream kinases (e.g., Akt) or phosphatases.

3. Advancing biomarker development: Combining PRAS40 mRNA expression levels with protein phosphorylation levels at key sites such as Thr246 to construct multi-parameter prognostic prediction models may further improve accuracy. Explore its expression or modification state in circulating tumor cells or exosomes to enable non-invasive efficacy monitoring and prognosis assessment.

6. Which manufacturers provide PRAS40 (T246) recombinant rabbit monoclonal antibodies?

Hangzhou Start Biotech Co., Ltd. has independently developed the "Phospho-PRAS40 (T246) Recombinant Rabbit Monoclonal Antibody" (product name: Phospho-PRAS40 (T246) Recombinant Rabbit mAb (S-977-7), This product is a high-specificity, highly sensitive, and exceptionally stable detection tool for key mTORC1 signaling pathway substrate activity. Developed using recombinant rabbit monoclonal antibody technology, it has been rigorously validated across various platforms, including Western Blot (WB) and immunofluorescence (IF), and holds significant application value in cell growth, metabolic regulation, and tumorigenesis research.

Professional technical support: We provide comprehensive product technical documentation, including examples of phosphorylation dynamics under insulin stimulation time gradients, research recommendations for co-precipitation with total PRAS14-3-3 binding proteins, and specialized technical consultation to assist clients in achieving precise and reliable discoveries in cell growth and metabolic regulation.

Hangzhou Start Biotech Co., Ltd. is committed to providing high-quality, high-value biological reagents and solutions to global innovative pharmaceutical companies and research institutions. For more details about the "Phospho-PRAS40 (T246) Recombinant Rabbit Monoclonal Antibody" or to request sample testing, please contact us.

```

Product Information